C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01)
Patent
CA 2581086
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the .beta.1-adrenergic receptor (AR).
L'invention concerne l'utilisation de procédés d'évaluation d'un traitement faisant intervenir du bucindolol pour un patient, en particulier un patient souffrant d'insuffisance cardiaque. L'invention concerne des procédés permettant de déterminer s'il convient d'administrer ou de prescrire du bucindolol à un patient si ce dernier est homozygote pour le polymorphisme Arg 389 dans le récepteur ß1-adrénergique (AR).
Bristow Michael
Liggett Stephen B.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
The Regents Of The University Of Colorado A. Body Corporate
The University Of Cincinnati
LandOfFree
Method for treatment with bucindolol based on genetic targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment with bucindolol based on genetic targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment with bucindolol based on genetic targeting will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1465767